Evidence map›Paper›PMID 33591412›Full record

ArticleCancer immunology, immunotherapy : CII2021

Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration.

Keiichiro Mori, Irene Resch, Noriyoshi Miura, Ekaterina Laukhtina, Victor M Schuettfort, Benjamin Pradere, Satoshi Katayama, David D'Andrea, Mehdi Kardoust Parizi, Mohammad Abufaraj and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 6 pooled it
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 12 countries.

Keiichiro MoriDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-6147-6569
Irene ReschDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Noriyoshi MiuraDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Ekaterina LaukhtinaDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Victor M SchuettfortDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Benjamin PradereDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Satoshi KatayamaDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
David D'AndreaDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Mehdi Kardoust PariziDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Mohammad AbufarajDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Wataru FukuokayaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Claudia Collà RuvoloCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
Stefano LuzzagoCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
Sophie KnipperCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
Carlotta PalumboCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
Alberto BrigantiDepartment of Urology, Vita Salute San Raffaele University, Milan, Italy.
Dmitry V EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Morgan RouprêtUrology department, Sorbonne Université, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, GRC n°5, 75013, Paris, France.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shin EgawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
McGill University Health Centre · CAJikei University School of Medicine · JPMedical University of Vienna · ATSechenov University · RUUniversität Hamburg · DEUniversity of Jordan · JOEhime University · JPOkayama University · JPShariati Hospital · IRSorbonne Université · FRThe University of Texas Southwestern Medical Center · USUniversité de Tours · FRVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the prognostic role of the preoperative systemic immune-inflammation index (SII) in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). MATERIALS AND

methodsWe retrospectively analyzed our multi-institutional database to identify 2492 patients. SII was calculated as platelet count × neutrophil/lymphocyte count and evaluated at a cutoff of 485. Logistic regression analyses were performed to investigate the association of SII with muscle-invasive and non-organ-confined (NOC) disease. Cox regression analyses were performed to investigate the association of SII with recurrence-free, cancer-specific, and overall survival (RFS/CSS/OS).

resultsOverall, 986 (41.6%) patients had an SII > 485. On univariable logistic regression analyses, SII > 485 was associated with a higher risk of muscle-invasive (P = 0.004) and NOC (P = 0.03) disease at RNU. On multivariable logistic regression, SII remained independently associated with muscle-invasive disease (P = 0.01). On univariable Cox regression analyses, SII > 485 was associated with shorter RFS (P = 0.002), CSS (P = 0.002) and OS (P = 0.004). On multivariable Cox regression analyses SII remained independently associated with survival outcomes (all P < 0.05). Addition of SII to the multivariable models improved their discrimination of the models for predicting muscle-invasive disease (P = 0.02). However, all area under the curve and C-indexes increased by < 0.02 and it did not improve net benefit on decision curve analysis.

conclusionsPreoperative altered SII is significantly associated with higher pathologic stages and worse survival outcomes in patients treated with RNU for UTUC. However, the SII appears to have relatively limited incremental additive value in clinical use. Further study of SII in prognosticating UTUC is warranted before routine use in clinical algorithms.

Indexed as

BiomarkersImmunityHumansInflammationLeukocyte CountLymphocyte CountMaleOdds RatioPlatelet CountPrognosisRecurrenceUrologic NeoplasmsBiomarkersNephroureterectomySystemic immune–inflammation indexUpper tract urothelial carcinoma

Identifiers

PMID33591412
PMCPMC8360829
OpenAlexW3132281503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.